Global Megestrol Acetate (Megace) Market Size By Type (Suspension, Tablets), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Megestrol Acetate (Megace) Market was valued at USD 412 million in 2023 and is projected to reach USD 645 million by 2031, growing at a CAGR of 5.8% during the forecast period from 2023 to 2031. This growth is driven by the rising prevalence of cancer and HIV/AIDS, where Megestrol Acetate is commonly used to manage cachexia (wasting syndrome) and appetite loss. Increasing geriatric population, advancements in drug formulations, and expanding awareness about palliative care are further fueling market demand. Additionally, the drug’s off-label uses for treating severe appetite loss and weight loss across various conditions continue to support its widespread adoption.

Drivers:

1. Rising Incidence of Cancer and HIV/AIDS:

Megestrol Acetate is widely prescribed for anorexia and cachexia in cancer and HIV/AIDS patients. The growing patient base for these diseases significantly boosts the market.

2. Increasing Geriatric Population:

Older adults are more susceptible to chronic illness and weight loss, for which Megestrol Acetate is frequently recommended. The aging global population supports sustained demand.

3. Advancements in Drug Formulations:

Newer, more bioavailable oral suspension formulations and extended-release versions of Megestrol Acetate enhance patient compliance and therapeutic efficacy.

Restraints:

1. Side Effects and Safety Concerns:

Adverse effects like thromboembolism, fluid retention, and endocrine disruptions limit Megestrol Acetate’s use, especially in high-risk populations.

2. Regulatory Restrictions and Off-label Use Scrutiny:

Although widely used off-label, strict regulations in some regions hinder promotional and prescribing flexibility, limiting market expansion.

Opportunity:

1. Expansion in Emerging Markets:

Rising healthcare infrastructure in Asia-Pacific, Latin America, and Africa opens significant growth opportunities for generic Megestrol Acetate formulations.

2. Increased Use in Palliative and Geriatric Care:

The rising adoption of palliative care programs globally paves the way for higher usage of Megestrol Acetate for symptom relief in non-oncology settings.

Market by System Type Insights:

The oral suspension segment holds the largest market share due to its higher bioavailability and ease of administration in patients with difficulty swallowing. However, the tablet form continues to be widely used in long-term treatment settings due to convenience and cost-effectiveness. The increasing availability of extended-release formulations is expected to further diversify product preferences in the coming years.

Market by End-use Insights:

Hospitals represent the leading end-user segment, driven by the high prevalence of cancer and HIV/AIDS treatments in inpatient settings. Retail pharmacies are also significant contributors, as Megestrol Acetate is often prescribed for outpatient use. Additionally, long-term care facilities are an emerging segment, aligned with the increasing demand for geriatric appetite-stimulating therapies.

Market by Regional Insights:

North America dominated the global Megestrol Acetate market in 2023, owing to a strong pharmaceutical distribution network, high disease burden, and widespread adoption of palliative care. Europe follows closely due to supportive reimbursement policies. However, the Asia-Pacific region is expected to experience the highest CAGR through 2031, driven by expanding healthcare access, generics penetration, and growing cancer incidence.

Competitive Scenario:

Leading players in the global Megestrol Acetate market include Pfizer Inc., Mylan N.V. (Viatris), Teva Pharmaceutical Industries Ltd., Novartis AG, and Par Pharmaceutical (Endo International). These companies focus on expanding their generic portfolios, securing regulatory approvals, and entering untapped regional markets. For example:

In 2023, Mylan launched a new high-concentration Megestrol Acetate oral suspension for improved patient compliance.

Pfizer expanded its oncology care range in Asia-Pacific, including palliative support medications such as Megace.

Teva Pharmaceuticals emphasized cost-effective generics in developing economies to widen market access.

Scope of Work – Global Megestrol Acetate (Megace) Market

Key Market Developments:

2023: Teva Pharmaceuticals received FDA approval for a new formulation of Megestrol Acetate oral suspension.

2024: Pfizer initiated clinical trials to evaluate Megestrol Acetate’s efficacy in appetite stimulation among elderly patients with dementia.

2025: Mylan introduced a value-based pricing strategy in Latin America to increase access to Megestrol Acetate for cancer-related cachexia.

FAQs:

1) What is the current market size of the Global Megestrol Acetate (Megace) Market?

The market was valued at USD 412 million in 2023.

2) What is the major growth driver of the Global Megestrol Acetate (Megace) Market?

The key driver is the rising prevalence of cancer and HIV/AIDS, where Megestrol Acetate is widely used for treating appetite loss and cachexia.

3) Which is the largest region during the forecast period in the Global Megestrol Acetate (Megace) Market?

North America is projected to remain the largest regional market through 2031.

4) Which segment accounted for the largest market share in the Global Megestrol Acetate (Megace) Market?

The oral suspension segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Megestrol Acetate (Megace) Market?

Key players include Pfizer Inc., Mylan N.V. (Viatris), Teva Pharmaceutical Industries Ltd., Par Pharmaceutical, and Novartis AG.